目的：分析T2N0M0上尿路尿路上皮癌（upper tract urothelial carcinoma, UTUC）患者长期生存情况以及预后相关因素。方法：回顾性分析2000年1月至2013年12月于北京大学第一医院行手术治疗的T2N0M0 UTUC患者的临床和随访资料，应用Kaplan-Meier法计算生存率，Log-rank方法进行单因素分析，对单因素分析中有统计学差异的变量采用Cox模型进行多因素生存分析。结果：共235例T2N0M0 UTUC患者纳入研究，中位随访时间53（3~142）个月。入组患者中男性95例（40.4%），女性140例（59.6%）；患者平均年龄（66.73 ±10.49）岁，末次随访时共有74例（31.5%）患者因肿瘤死亡，96 例（40.9%）患者出现膀胱复发，中位死亡时间及复发时间分别为35个月和19.5个月。患者的3年和5年肿瘤特异性生存率分别为89.1%和85.9%；3年和5年无复发生存率分别为85.5%和80.2%。多因素分析发现，年龄大于55岁 (HR=3.138, 95%CI: 1.348~7.306, P=0.008)和肿瘤直径大于5 cm (HR=3.320, 95%CI: 1.882~5.857, P<0.001)是T2N0M0 UTUC患者术后肿瘤特异性死亡的独立危险因素；肿瘤发生在输尿管（HR=1.757, 95%CI: 1.159~2.664, P=0.008）和肿瘤低分级（HR=1.760, 95% CI: 1.151~2.692, P=0.009） 是T2N0M0膀胱复发的危险因素。结论：T2N0M0 UTUC患者肿瘤特异性生存预后较好，肿瘤复发率同非浸润性UTUC相当，但复发较早。肿瘤直径大于5 cm和年龄大于55岁是T2N0M0 UTUC肿瘤特异性死亡的独立危险因素；肿瘤发生在输尿管和肿瘤低分级是T2N0M0 UTUC膀胱复发的危险因素。

Objective： To evaluate the impacts of the prognostic factors of T2N0M0 upper tract urothelial carcinoma (UTUC) for Chinese patients. Methods: A retrospective study was conducted including 235 patients who were diagnosed with T2N0M0 UTUC in our hospital and received radical nephroureterectomy (RNU) or partial ureterectomy during January 2000 and December 2013. The 3 and 5-year can-cer-specific survival rates and bladder recurrence-free survival rates of all the patients were valued using Kaplan-Meier method, and the survival curves with statistical significance between the two were compared using the Log-rank test. Variables with significant differences in the univariate analysis were subjected to the multivariate analysis by Cox regression model. Results: A total of 235 patients were included in this study, including 95 (40.4%) male patients and 140 (59.6%) female patients. The mean age was 66.73±10.49 years.The median follow-up time was 53 (rang: 3－142) months, and during the follow-up, 74 (31.5%) patients died of UTUC after a median of 35 months，and 96 (40.9%) patients developed intravesical recurrence after a median of 19.5 months. The 3 and 5year cancer-specific survival rates of all the patients were 89.1% and 85.9%, respectively; the bladder recurrence-free survival rates were 85.5% and 80.2%, respectively. The independent prognostic factors of cancer-specific mortality were tumor age elder than 55 years (HR=3.138, 95%CI: 1.348－7.306, P=0.008) and diameter larger than 5 cm (HR=3.320, 95%CI: 1.882－5.857, P<0.001). The independent prognostic factors of bladder recurrence-free survival were ureter tumor (HR=1.757, 95%CI: 1.159－2.664, P=0.008) and lower tumor grade (HR=1.760, 95% CI: 1.151－2.692, P=0.009). Conclusion: T2N0M0 UTUC has a better cancer-specific survival. The intravesical recurrence was equivalent to non-muscle invasive UTUC but earlier. The tumor diameter larger than 5 cm and the patient age elder than 55 years were independently associated with cancerspecific mortality; the primary tumor located in ureter and lower tumor grade were more likely to develop intravesical recurrence.